Diverse Lenabasum pathway activation in dermatomyositis patients' blood.

ABSTRACT: Lenabasum, a non-psychoactive cannabinoid type-2 receptor (CB2R) agonist, has shown promise in reducing cutaneous disease in Dermatomyositis (DM) patients. Lenabasum activates two distinct receptors: CB2R and the nuclear peroxisome proliferator-activated receptor-γ (PPARγ). Our goal was to investigate the dominant mechanism of action leading to pathogenic IFNβ reduction by lenabasum (through CB2R or PPARγ) across leukocytes. We utilized whole blood leukocytes from 14 DM patients and grouped patients as in vitro responders or non-responders. We stimulated leukocytes in vitro in the presence of CB2R and PPARγ inhibitors and lenabasum. Intracellular and extracellular marker expression was analyzed by flow cytometry. CD4⁺ T (p < 0.05), monocyte-derived dendritic cells (p = 0.06), an

SUBMITTER: Kodali N 

PROVIDER: S-EPMC12086228 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature